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patients with early gastric cancer (eGc) who undergo non-curative endoscopic resection (eR) require 
additional surgery. the aim of the study was to validate surgical and oncological outcomes according to 
the timing of additional surgery after non-curative endoscopic resection. We retrospectively analyzed 
long-term follow-up data on the 302 patients enrolled between January 2007 and December 2014. 
We validated our earlier suggestion that the optimal time interval from non-curative eR to additional 
surgery was 29 days. All patients were divided into two groups by reference to time intervals from 
eR to additional surgery of ≤29days (n = 133; group A) and >29 days (n = 169; group B). The median 
follow-up duration was 41.98 ± 21.23 months. As in our previous study, group B exhibited better 
surgical outcomes. A total of 10 patients developed locoregional or distant recurrences during the 
follow-up period, but no significant difference was evident between the two groups. Interestingly, 
the survival rate was better in group B. Group B (>29 days) exhibited better surgical and oncological 
outcomes. Thus, additional gastrectomy after non-curative ER should be delayed for 1 month to ensure 
optimal surgical and oncological outcomes.
Gastric cancer (GC) is a major health problem worldwide, with an estimated 1 million new cases per year1. Early 
gastric cancer (EGC) is defined as a lesion confined to the mucosa or the submucosa, regardless of the presence of 
regional lymph node metastasis (LNM), and some of them can be cured via endoscopic resection (ER)2–4. ER for 
EGC plays a central role in the treatment of EGC, and due to the development of the endoscopic technology and 
instrument, extended criteria are being applied beyond the absolute indication for ER, nowadays5–7. Although 
ER has the advantage of preserving the stomach, is minimally invasive, and affords a better quality of life than 
open surgery, ER sometimes fails to completely remove a lesion8. The rates of non-curative ER range from 15.3 
to 16.7%9–11. Patients with non-curative ER typically require additional treatment such as re-ER, ablation ther-
apy, and/or gastrectomy12–14. However, additional surgical gastrectomy with lymph node dissection is generally 
recommended after non-curative ER because of the possibility of LNM and the unfavorable prognosis7,13,15,16. 
However, the optimal timing of additional surgery after non-curative ER remains unclear. In our previous study, 
we evaluated the time interval between ER and additional surgery in terms of surgical and oncological out-
comes17. We found that the interval affected the surgical outcomes17.
ER-associated electrocoagulation creates a large iatrogenic ulcer requiring 4–8 weeks for complete healing. 
Also, ER may cause edema, fibrosis, and even adhesions of both the stomach and surrounding tissues, which 
may be increasing the surgical difficulties during subsequent gastrectomy18,19. However, waiting for the healing of 
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edema or ulceration after ER in cancer patients may allow for tumor to grow and increase the risk of recurrence. 
Another essential aspect that must also be taken to account is the potential impact of treatment delay on patient 
anxiety. Although patients know that it is necessary to wait for a treatment, it is experienced as a suffering time of 
anxiety and fear. Many surgeons plan the timing of operation after non-curative ER by reference to their surgical 
schedules or other subjective factors. It is important to objectively evaluate the optimal effect of the time interval 
of additional gastrectomy after ER on surgical outcome.
Our previous study suggested an optimal time interval between non-curative ER and additional surgery; 
however, the work had certain limitations, including a relatively small number of patients and only short-term 
follow-up. We thus could not confirm the oncological outcomes. Here, we analyze long-term follow-up data to 
validate the surgical outcomes and evaluate the oncological outcomes associated with our previously proposed 
optimal time interval from non-curative ER to additional surgery.
Results
clinicopathological characteristics and surgical outcomes. Baseline clinicopathological charac-
teristics and surgical outcomes are shown in Table 1. The mean patient age was 60.53 (±12.23) years. ER was 
non-curative in a total of 85 patients (28.1%) for at least two reasons, including lateral or vertical margin involve-
ment combined with LVI. Most patients underwent laparoscopic gastrectomy and the mean operative time was 
188.97 ± 73.96 min. After gastrectomy, 44 (14.6%) patients had residual cancer and 26 (9.5%) LNM. In our pre-
vious short-term follow up study, there are 16.2% residual cancer and 9.7% LNM17. A total of 145 (48%) patients 
developed postoperative complications and the incidence of major complications was 5.3%. The mean follow-up 
period after surgery was 41.98 ± 21.23 months, which is longer than 26.7 ± 16.4 months of the previous study.
The relationship between time interval and major complications. To validate the perioperative 
safety of patients who underwent additional surgery, we analyzed the relationship between the time from ER to 
additional surgery and the major complications by drawing a receiver-operating characteristic (ROC) curve. The 
area under the curve (AUC) was 0.579 (95% CI, 0.521–0.635), associated with a sensitivity of 50% and a specificity 
of 56.7% (Supplemental Fig. 1). These results suggest that the time interval of additional surgery did not affect the 
incidence of major complications.
The optimal time interval between ER and additional surgery. We sought correlations between the 
time to additional surgery and the difficulty of that surgery. The raw data on the time from ER to surgery, and the 
operative time and EBL, are plotted in Supplemental Fig. 2. The operative time and the EBL decreased signifi-
cantly as the time interval increased (r = −0292, P < 0.001, and r = −0.135, P = 0.019, respectively).
We next performed one-way MANOVA to validate the optimal time interval (29 days) between non-curative 
ER and surgery identified in our previous study. In our previous study, we analyzed the correlation between the 
time interval of additive surgery and the difficulty of surgery by using one- way MANOVA. The time interval 
point, at which the operative time and the EBL of the earlier operation group and the later operation group 
showed the greatest disparities. This difference was most pronounced at day 2917. In this study, differences 
between the early and later surgical group were evident over the time interval (25–35 days). The differences were 
greatest on day 29, at which time the slopes of the graphs changed direction. We thus confirmed that 29 days was 
the appropriate cut-off point. No significant between-group difference was apparent from after day 36 (Fig. 1, 
Supplemental Fig. 3).
Short-term surgical outcomes of both groups. Table 2 compares the two groups by time to surgery 
after ER. Of the 302 patients, 133 (44.0%) were in the earlier operation group (≤29 days; group A), and 169 (56%) 
in the later operation group (>29 days; group B). In our previous study, there are 78 (50.6%) were categorized as 
group A, and 76 (49.4%) as group B17. The percentage of patients in group B was more than in our previous study. 
The two groups did not differ significantly in terms of any of age, sex, body mass index, comorbidities except for 
tumor size, or ER specimen size. In the later operation group, the operative time, the EBL, the number of periop-
erative transfusions, the time to drain removal, the drainage volume on postoperative day (POD) 1, the maximal 
postoperative C-reactive protein (CRP) level, and the duration of postoperative hospital stay were all better than 
that of the early operation group. The groups did not differ in terms of the numbers of overall or major postoper-
ative complications, or locoregional or distant recurrences.
Supplemental Fig. 4 shows the data on perioperative surgical outcomes, including the CRP levels, the white 
blood cell (WBC) counts, and drainage volumes. There was no significant between-group difference except in 
terms of the POD 1 drainage volume, as mentioned above.
Long-term oncological outcomes of both groups. The median follow-up times after surgery were 
37.02 ± 20.54 and 44.18 ± 19.49 months in the early operation and later operation groups, respectively (P = 0.002). 
During the follow-up period, six patients of the early operation group and four of the later operation group expe-
rienced recurrences. In the early operation group, distant metastasis occurred in four patients and locoregional 
recurrence in two. The former four patients died; their characteristics are described in Supplementary Table 1. 
The median survival time was estimated to be 58.6 months in the Group A (≤29days) and 62.7 months in the 
Group B (>29days). In the all patients, the median survival time was 61.8 months. The 5-year survival rates were 
as follows: Group A (≤29days): 92%, Group B (>29days): 99%. There was no significant difference in the 5-year 
survival rate of two groups.
The recurrence rates did not differ significantly between the groups. Interestingly, the survival rate was better 
in the later operation group than the early group (Fig. 2). Of factors possibly affecting recurrence and survival, 
LNM was significant in both univariate and multivariate analyses (Tables 3 and 4; Supplementary Fig. 5).
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Characteristics Value
Age, (year, mean ± SD) 60.53 ± 12.23
Male, no. (%) 215 (71.2)
BMI, (kg/m2, mean ± SD) 23.43 ± 3.18
Comorbidity, no. (%) 168 (55.6)
ASA score, no. (%)
1 146 (48.3)
2 115 (38.1)
3 40 (13.3)
4 1 (0.3)
Longitudinal location, no. (%)
Upper one-third 44 (14.6)
Mid one-third 127 (42.1)
Lower one-third 131 (43.3)
Cross-sectional location, no. (%)
Anterior wall 61 (20.2)
Posterior wall 75 (24.8)
Lesser curvature 100 (33.1)
Greater curvature 66 (21.9)
Gross type, no. (%)
Elevated 130 (43.1)
Flat 78 (25.8)
Depressed 94 (31.1)
WHO classification, no. (%)
Well differentiated 85 (28.1)
Moderately differentiated 125 (41.5)
Poorly differentiated 49 (16.2)
Signet ring cell 39 (12.9)
Carcinoma with lymphoid stroma 4 (1.3)
Lauren classification, no. (%)
Intestinal 221 (73.3)
Diffuse 35 (11.7)
Mixed 25 (8.3)
ǂUnknown 16 (5.4)
Underterminate 4 (1.3)
Tumor size, (cm, mean ± SD) 2.34 ± 1.40
ER specimen size, (cm, mean ± SD) 3.64 ± 1.69
Cause of additive surgery, no. (%)
Resection margin
Lateral margin (+) 34 (11.3)
Vertical margin (+) 66 (21.9)
LVI, no. (%) 65 (21.5)
*Others, no. (%) 14 (4.6)
More than two, no. (%) 85 (28.1)
Operation type, no. (%)
Laparoscopic 273 (90.4)
Open 29 (9.6)
Resection extent, no. (%)
Total 47 (15.6)
ƗSubtotal 255 (84.4)
Extent of lymphadenectomy, no. (%)
D1 + α 16 (5.3)
D1 + β 229 (75.8)
D2 57 (18.9)
Residual cancer, no. (%) 44 (14.6)
Harvested lymph node, (no, mean ± SD) 37.14 ± 15.54
Lymph node metastasis, no. (%) 26 (9.5)
Continued
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Discussion
In this long-term follow-up study, we found that additional surgery performed about 1 month after ER afforded 
better short-term surgical outcomes and long-term oncological safety. Minimally invasive surgery for the treat-
ment of EGC has increased in popularity, and many reports have addressed learning curve effects in terms of 
laparoscopy-assisted gastrectomy; operative time, extent of intraoperative bleeding, and postoperative compli-
cation rate fell with increasing surgical experience20–22. Another study found that a longer operation time, more 
bleeding, and more frequent transfusion were all associated with more challenging and difficult operations23. We 
evaluated perioperative patient safety using the Clavien–Dindo system; such safety is the highest priority when 
planning surgery24–26. We found no significant relationship between the major complication rate and the time to 
surgery after ER. This means that there is no relationship between the additional surgery time interval after ER 
and the important complications that may occur in the patient.
Second to surgical complications, the operative time, and EBL would be applied as next endpoints to estimate 
operative feasibility. In these respects, we evaluated the association between time interval of additioanl surgery 
after non-curative ER and the two factors, operative time and EBL. As shown in the results, these parameters 
tended to decrease as the time interval increased. In our previous study, we used the MANOVA test to define the 
time from ER at which the later operative time and the EBL differed maximally between an early and later oper-
ation group; we employed the same method here. The greatest differences (reflected by changes in the slopes of 
the graphs) were evident 29 days after ER. Many studies have reported that ER-induced ulcers are usually in the 
healing or scarring stage 4–8 weeks after ER27–30. ER-induced inflammation and the lack of ulcer healing may ren-
der early operation (within 4 weeks) more difficult than later operation. Also, the postoperative hospital stay was 
Characteristics Value
Operation time, (min, mean ± SD) 188.97 ± 73.96
EBL, (cc, mean ± SD) 108.35 ± 295.67
Perioperative transfusion, no. (%) 4 (1.3)
Time to first flatus, (day, mean ± SD) 3.43 ± 0.99
Time to start liquid diet, (day, mean ± SD) 3.48 ± 2.43
Postoperative hospital day, (day, mean ± SD) 8.65 ± 6.59
Time of drain removal, (day, mean ± SD) 3.05 ± 3.49
Maximal postoperative CRP, (mg/L, mean ± SD) 82.69 ± 73.51
Maximal postoperative WBC, (103/µL, mean ± SD) 12.87 ± 3.61
Postoperative overall complication, no. (%) 145 (48.0)
Postoperative major complication, no. (%) 16 (5.3)
Follow-up period, (months, mean ± SD) 41.98 ± 21.23
Table 1. Baseline clinicopathological characteristics and surgical outcomes. *Others: Poorly differentiated 
adenocarcinoma with signet ring cell features, Unknown resection margin due to fragmentation. †Two 
cases of pylorus-preserving gastrectomy are included in the category of subtotal gastrectomy. ‡There is no 
mentioned about pathological report SD, standard deviation; BMI, body mass index; ASA, American Society 
of Anesthesiologists; WHO, World Health Organization; ER, Endoscopic resection; LVI, Lymphovascular 
invasion; CRP, c-reactive protein; WBC, white blood cell; EBL, estimated intraoperative blood loss.
Figure 1. The time intervals since endoscopic resection (days) associated with the greatest differences between 
the amounts of blood loss and the operative times in the early and later groups were evaluated with the aid of 
the MANOVA test. The relationship between the time elapsed since endoscopic resection and a combination of 
operative time and the amount of intraoperative blood loss. The greatest difference and the change of the slope 
of the graph was around day 29 (the cut-off point), and no significant difference was evident from after day 36.
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significantly shorter in the later operative group. In recent years, the length of stay has been emphasized not only 
as an indicator of healthcare costs, but also because it is closely related to complications associated with surgery, 
and surgical outcomes31–33. Between-group differences were evident in terms of the WBC counts, CRP levels, and 
drainage volumes; these are all markers of surgical trauma34,35. Therefore, our long-term follow-up study validated 
our earlier suggestion that the optimal time interval from ER to additional surgery was about 1 month.
Characteristics
Group A (≤29days) 
(n = 133)
Group B (>29days) 
(n = 169) P
Age, (years, mean ± SD) 62.04 ± 9.17 61.14 ± 9.76 0.417
Male, no. (%) 90 (67.7) 125 (74.0) 0.142
BMI, (kg/m2, mean ± SD) 23.77 ± 3.12 23.24 ± 2.73 0.117
Comorbidity, no. (%) 68 (51.1) 100 (59.2) 0.162
ASA score, no. (%) 0.039
   1 73 (54.9) 73 (43.2)
   2 40 (30.1) 75 (44.4)
   3 19 (14.3) 21 (12.4)
   4 1 (0.7) 0 (0.0)
Tumor size, (cm, mean ± SD) 2.62 ± 1.61 2.20 ± 1.30 0.011
ER specimen size, (cm, mean ± SD) 4.10 ± 1.71 3.29 ± 1.56 <0.001
Operation type, no. (%) 0.486
   Laparoscopic 122 (91.7) 151 (89.3)
   Open 11 (8.3) 18 (10.7)
Resection extent, no. (%) 0.150
   Total 24 (18.0) 23 (13.6)
   Subtotal 109 (82.0) 146 (86.4)
Type of reconstruction, no. (%) 0.090
   Billroth I 74 (55.6) 85 (50.3)
   Billroth II 25 (18.8) 49 (29.0)
   Roux-en-Y 32 (24.1) 35 (20.7)
   Gastro-gastrostomy 2 (1.5) 0 (0.0)
Extent of lymphadenectomy, no. (%) 0.019
   D1 (α + β) 111 (83.5) 135 (79.9)
   D2 22 (16.5) 34 (20.1)
Harvested LN, (no, mean ± SD) 39.86 ± 17.47 34.99 ± 13.49 0.007
Existence of metastatic LN, no. (%) 0.292
   Yes 14 (10.5) 12 (7.1)
   No 119 (89.5) 157 (92.9)
Operation time, (min, mean ± SD) 210.67 ± 76.72 173.01 ± 66.07 <0.001
EBL, (cc, mean ± SD) 414.95 ± 35.98 135.45 ± 10.42 0.010
Intraoperative transfusion, no. (%) 0.023
   Yes 4 (3.0) 0 (0.0)
   No 129 (97.0) 169 (100)
Time to first flatus, (day, mean ± SD) 3.45 ± 1.01 3.43 ± 0.93 0.823
Time to start liquid diet, (day, mean ± SD) 3.65 ± 2.13 3.37 ± 2.63 0.330
Time of drain removal, (day, mean ± SD) 4.20 ± 4.19 3.36 ± 3.29 0.050
POD#1 drain discharge, (cc, mean ± SD) 159.92 ± 272.72 94.53 ± 144.84 0.008
POD#2 drain discharge, (cc, mean ± SD) 98.74 ± 123.79 83.73 ± 132.86 0.321
Maximal postoperative CRP, (mg/L, mean ± SD) 96.48 ± 73.05 74.40 ± 72.41 0.009
Maximal postoperative WBC, (103/µL, mean ± SD) 13.21 ± 3.49 12.79 ± 3.56 0.211
Postoperative overall complication, no. (%) 66 (49.6) 79 (46.7) 0.619
Postoperative major complication, no. (%) 10 (7.5) 6 (3.6) 0.126
Postoperative hospital day, (day, mean ± SD) 10.05 ± 8.17 7.60 ± 4.74 0.001
Follow-up period, (months, mean ± SD) 37.02 ± 20.54 44.18 ± 19.49 0.002
Locoregional recurrence, no. (%) 2 (1.5) 2 (1.2) 0.784
Distant recurrence, no. (%) 4 (3.0) 2 (1.2) 0.409
Table 2. Comparison between Two Groups according to Surgery Time after ER SD, standard deviation; BMI, 
body mass index; ASA, American Society of Anesthesiologists; LN, Lymph node; ER, Endoscopic Resection; 
EBL, Estimated blood loss; CRP, c-reactive protein; WBC, white blood cell; POD, Post-operative day; EBL, 
estimated intraoperative blood loss.
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We performed subgroup analysis by surgical experience (Supplementary Table 2). We defined a group of expe-
rienced surgeons in previous studies as surgeons with more than five years of experience in gastric surgery. Group 
A was 46.6% (62/133) and Group B was 65.7% (111/169). Because the experienced surgeon rate of the earlier 
operation group (≤29days; group A) is lower than the later operation group (>29 days; group B), we performed 
subgroup analysis for patients in the experienced surgeon group in order to correct the surgeon specific variable 
factor. On subgroup analysis in the experienced surgeon group, the operative time and postoperative hospital 
stay of patients in the early operation group were significantly longer than in the later group. In the late group, 
the EBL was significantly lower than in the early operation group. But there is no difference recurrence between 
two groups.
In this long-term follow-up study, we also evaluated oncological outcomes in terms of the optimal timing of 
surgery. As mentioned above, during follow-up, 10 patients experienced locoregional or distant recurrences, of 
whom 6 were in the early and 4 in the later operation group. The recurrence incidence did not differ between the 
two groups, but the survival rate did; more patients operated upon early rather than late developed LNM, sug-
gesting that the biological behavior of the cancer was prognostically more important than the time between ER 
and surgery. Recently, the requirement for perioperative blood transfusion and the extent of intraoperative blood 
loss have been suggested to be potentially (negatively) prognostic in terms of long-term outcomes36–38. This may 
be why the survival rate of our early operation group was poorer than that of the later group.
The limitations of our study include the retrospective design of the work and the inclusion of patients treated 
in only two tertiary centers. Additional prospective multicenter studies are needed to validate our findings. 
However, we validated our earlier study on the optimal timing of additional gastrectomy after non-curative ER, 
and our work may be of assistance to other surgeons.
In conclusion, we suggest that the interval between non-curative ER and additional gastrectomy should be 
about 1 month. This was associated with better surgical outcomes and oncological safety than earlier surgery.
Methods
Study population. We retrospectively collected data on patients diagnosed with EGC who underwent ER at 
the Severance and Gangnam Severance Hospitals, Yonsei University College of Medicine, Seoul, Korea, between 
January 2007 and December 2014. A total of 2,743 such patients were enrolled. Of these, 330 (12.0%) underwent 
non-curative ER as revealed histologically, and therefore required additional surgery. We excluded patients with 
any other malignancies, those who underwent combined operations, those who underwent emergency operations 
Figure 2. Kaplan–Meier plots of overall recurrence and survival. (A) The recurrence-free rate curve of those for 
whom the interval between endoscopic resection (ER) and additional surgery was 29 days. (B) The survival rate 
curve of such patients. The recurrence-free rate did not differ after the later operation, but the survival rate did.
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to treat ER complications (such as perforation or bleeding), and those who died because of other malignancies. 
We performed long-term follow-up on 154 patients enrolled in our previous study and a further 148 patients. 
Thus, in total, we analyzed 302 patients who underwent additional gastrectomy after non-curative ER.
The indications for ER included the expanded criteria: (1) a differentiated intramucosal adenocarcinoma 
≤3 cm in diameter, without lymphovascular invasion (LVI), irrespective of ulceration status; (2) a differentiated 
intramucosal adenocarcinoma without LVI or ulceration, irrespective of tumor diameter; (3) an undifferentiated 
intramucosal cancer ≤2 cm in diameter, without LVI or ulceration; and, (4) a differentiated adenocarcinoma 
≤ 3 cm in diameter exhibiting minimal submucosal invasion, without LVI7,39. EGC patients who underwent 
non-curative ER included those with incomplete margin resections, or LVI, or who otherwise did not fall within 
(exceeded) the expanded ER criteria39.
We analyzed clinicopathological characteristics, comorbidities, American Society of Anesthesiologists (ASA) 
scores, surgical outcomes (operative time and estimated intraoperative blood loss [EBL]), postoperative com-
plications, and oncological outcomes (locoregional and distant recurrences). Postoperative complications were 
graded using the Clavien–Dindo classification; complications of grade ≥III were defined as ‘major,’ being poten-
tially life-threatening25,40.
The patients were divided into two groups depending on the time interval (a cutoff between 1 and 60 days; 
please see below) between ER and surgery. Then, the surgical outcomes of the earlier operation group (group A) 
and the later operation group (group B) were compared to identify the optimal time interval from non-curative 
ER to surgery.
Informed consent was obtained from all patients before the procedures. This study was approved by the 
Institutional Review Board of Yonsei University College of Medicine and was conducted in accordance with the 
ethical principles of the Declaration of Helsinki (IRB No. 3-2018-0022).
Statistical analysis. Categorical variables are presented as numbers with percentages and were compared 
using the chi- squared or Fisher’s exact test. Continuous variables are presented as means ± standard deviations 
and were compared with the aid of Student’s t-test. A P value <0.05 was considered to reflect statistical signifi-
cance. The relationship between the time interval from ER to surgery, and major complications, was evaluated 
by calculating the area under the receiver operating characteristic (AUROC) curve. Multivariate analyses of var-
iance (MANOVAs) were used to explore the effects of the time interval between non-curative ER and additional 
surgery on the later operative time and the EBL. When data points lay >1.5-fold of the interquartile range (IQR) 
above the third or below the first quartile (outliers), we treated them as missing when calculating operative times 
Univariable Multivariable
Factor HR (95% CI) P HR (95% CI) P
Age 1.010 (0.945–1.079) 0.768
Sex 0.677
   Male Reference
   Female 0.719 (0.152–3.405)
Time interval, day 0.121
   <29 Reference
   ≥29 0.367 (0.103–1.302)
Tumor location
   Upper Reference
   Middle 0.311 (0.059–1.636) 0.168
   Lower 0.421 (0.089–1.997) 0.276
Tumor size (cm)
   <2 Reference
   ≥2 0.610 (0.169–2.206) 0.451
T Stage
No residual tumor Reference
   T1a, T1b 0.819 (0.102–6.559) 0.851
   T2a, T3 4.852 (0.597–39.408) 0.139
LNM 0.001 0.010
   No Reference Reference
   Yes 8.678 (2.439–30.859) 6.061 (1.538–23.884)
LVI 0.036 0.197
   No Reference Reference
   Yes 3.933 (1.095–14.129) 2.500 (0.621–10.057)
Table 3. Univariable and Multivariable analysis according to Recurrence. LVI, Lymphovascular invasion; LNM, 
Lymph node metastasis; CI, confidence interval; HR, hazards ratio. Lymphovascular invasion (LVI) and Lymph 
node metastasis (LNM) are included in the multivariable model.
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and EBLs. The recurrence-free and overall survival rates of the two groups were calculated using the Kaplan–
Meier method. To identify risk factors for recurrence and survival after additional surgery, we performed both 
univariate and multivariate logistic regression analyses. Cox’s regression hazard model was used for the multivar-
iable analysis. We included only those variables that exhibited P values <0.1 on univariate analysis in the multi-
variable analysis. All statistical calculations were performed with the aid of SPSS version 23.0 (SPSS Inc., Chicago, 
IL, USA) and SAS MANOVA version 9.3 (SAS Inc., Cary, NC, USA).
Received: 21 February 2019; Accepted: 19 November 2019;
Published: xx xx xxxx
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